Semaglutide 1.7 mg: The Sub-Maximal Wegovy Dose (Weeks 13-16 or Sub-Max Maintenance)
1.7 mg is the buffer step between 1.0 mg and the 2.4 mg target — and an increasingly popular long-term maintenance setpoint for patients who want strong appetite suppression without the full 2.4 mg side-effect load.
Semaglutide 1.7 mg is unique to Wegovy's chronic-weight-management titration — Ozempic for diabetes doesn't use it because Ozempic's max dose is 2.0 mg. The 1.7 mg step exists to buffer the jump from 1.0 mg to the FDA-approved 2.4 mg weight-loss target. Per Wegovy's prescribing information, weeks 13-16 are spent at 1.7 mg before the final escalation to 2.4 mg maintenance.
Why 1.7 mg matters
Jumping from 1.0 mg to 2.4 mg in one step would be a 2.4× dose increase — far too aggressive for most patients to tolerate. The 1.7 mg intermediate step is 1.7× from 1.0 mg, which most patients tolerate with mild transient nausea similar to prior escalations.
Clinically, 1.7 mg produces meaningful additional appetite suppression vs 1.0 mg. STEP 1 trial subgroup analyses suggest the 1.7 mg block contributes ~2-3% additional body-weight reduction over the 4-week window for patients who continue losing weight at this dose.
1.7 mg as sub-maximal maintenance
An increasingly common pattern: patients reach 1.7 mg and choose to stay there indefinitely rather than escalating to 2.4 mg. The trade-off:
| 1.7 mg maintenance | 2.4 mg maintenance (Wegovy target) | |
|---|---|---|
| Mean total weight loss (STEP 1 subgroup) | ~12-15% | 15-17% |
| Side effect intensity | Moderate | More frequent GI symptoms |
| "Ozempic face" risk | Lower (slower loss rate) | Higher (faster loss rate) |
| Cost (Trimi annual plan) | $99/mo | $99/mo (same flat rate) |
Continue with Trimi
$99/mo annual plan covers any semaglutide titration dose. Same active ingredient as Wegovy.
Start your visitFAQs
Why is there a 1.7 mg step instead of going straight to 2.4 mg?
GI tolerance again. The jump from 1.0 mg to 2.4 mg is too large for most patients to tolerate in one step. The 1.7 mg intermediate step (weeks 13-16 per Wegovy protocol) buffers the increase. Wegovy is the only major brand that uses the 1.7 mg step; Ozempic skips it because its max dose is 2.0 mg.
How long do I stay at 1.7 mg?
4 weeks (weeks 13-16) per the standard Wegovy schedule. After 4 weeks at 1.7 mg, the next step is 2.4 mg maintenance dose. Patients can stay at 1.7 mg longer if they prefer a slower escalation, or hold at 1.7 mg as a sub-maximal maintenance dose.
Will I lose more weight at 1.7 mg vs 1.0 mg?
Modestly. The clinical effect difference between 1.0 mg and 1.7 mg is real but smaller than the 0.5→1.0 mg jump. Most patients lose an additional 2-4 lbs during the 4-week 1.7 mg block on top of cumulative loss from prior steps. Patients near goal weight may experience slowing rate of loss as their body approaches equilibrium.
Can I maintain at 1.7 mg long-term?
Yes — increasingly common as a sub-maximal maintenance dose for patients who don't want 2.4 mg side effects but want more than 1.0 mg can provide. The 1.7 mg dose offers ~12-15% mean weight loss in the STEP 1 trial subgroup analyses, vs ~10-12% at 1.0 mg and ~15-17% at 2.4 mg. Discuss long-term setpoint with your Trimi clinician.
Side effects at 1.7 mg?
Typically the same pattern as prior escalations — 5-10 days of transient symptom increase post-dose-change, then stabilization. Patients who tolerated 1.0 mg well usually tolerate 1.7 mg with mild transient symptoms.
Is 1.7 mg available in compounded semaglutide?
Yes. Compounded semaglutide via Trimi can be dosed at 1.7 mg by drawing the appropriate volume from the vial. Onboarding includes clear dose conversion instructions; clinician walks you through the math at each titration step.
Related reading
Disclaimer: Informational, not medical advice. Compounded semaglutide is prepared per individual prescription by a 503A community sterile compounding pharmacy; not FDA-approved as a finished drug. Always consult a licensed clinician about dose titration. **The FDA does not review or approve any compounded medications for safety or effectiveness.